EXOZYMES INC.
EXOZNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | — | — | $70,069 |
| Operating income | −$9.7M | −$5.9M | −$1.8M |
| Net income | −$9.2M | −$5.9M | −$2.0M |
| Total assets | $6.0M | $13.0M | $3.6M |
| Total liabilities | $2.6M | $2.6M | $3.9M |
| Equity | $3.4M | $10.4M | −$384,319 |
| EPS (diluted) | $-1.09 | $-0.89 | $-0.33 |
| Shares out. | 8.4M | 8.4M | 6.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −269.6%
- Return on assets
- −153.4%
- Return on capital (ROCE)
- −220.6%
- Liabilities / assets
- 43.1%
- Debt / equity
- 0.76×
- Book value / share
- $0.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -18.46distress
- Accruals / assets
- −44.5%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 11,977 | 5.0 | -4.7% |
| Apr 30, 2026 | 12,566 | 4.7 | +8.3% |
| Apr 15, 2026 | 11,605 | 1.1 | +8.8% |
| Mar 31, 2026 | 10,666 | 2.7 | +10.6% |
| Mar 13, 2026 | 9,642 | 2.6 | -0.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 7, 2026
- Other material eventApr 10, 2026
- Other material eventMar 31, 2026
- Other material eventFeb 5, 2026
- Other material eventDec 12, 2025
- Other material eventNov 13, 2025
- Other material eventOct 3, 2025
- Shareholder voteJul 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.